Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
This study has been completed.
AbbVie (prior sponsor, Abbott)
First Posted: March 9, 2012
Last Update Posted: October 31, 2014
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||October 2013|
|Primary Completion Date:||October 2013 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||October 24, 2014|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study. J Alzheimers Dis. 2016;51(4):1237-47. doi: 10.3233/JAD-150978.